– USA, MA – eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, announced the appointment of Dr. Doug Williams (Ph.D.) and Dr. Adam Craig (M.D., Ph.D.) to its Board of Directors.
About Dr. Douglas Williams
Doug Williams brings more than 30 years of leadership experience in the biopharmaceutical industry, including senior executive roles at Biogen, ZymoGenetics, Amgen, and Seattle Genetics. He has contributed to the development of several blockbuster therapies, including Enbrel, Tecfidera, and Spinraza. Most recently, he served as President of R&D at Sana Biotechnology and as founding CEO of Codiak Biosciences.
Dr. Doug Williams serves on the boards of Climb Bio (Chair) and CAMP4 Therapeutics.
About Dr. Adam Craig
Dr. Adam Craig is a biotechnology executive with over 25 years of global experience in drug development and commercialization, particularly in oncology, hematology, and rare diseases. He served as President and CEO of CTI BioPharma, leading to the approval and commercialization of Vonjo. He is Executive Chairman of X4 Pharmaceuticals and was recently interim CEO of Stratus Therapeutics.
Adam Craig held CMO and senior development roles at Sunesis Pharmaceuticals and Chemgenex Pharmaceuticals.
He serves on the board of Stratus Therapeutics.
Adam Craig is a Member of the Royal College of Physicians (U.K.) and holds medical and doctoral degrees from the University of London, a Ph.D. in Molecular Oncology from Leeds University, and an MBA from the Open Business School.
About eGenesis
eGenesis is pioneering a genome engineering-based approach to develop safe, effective transplantable organs to end the global organ shortage. Its platform uniquely addresses cross-species molecular incompatibilities and viral risk via its proprietary genetic engineering platform to improve outcomes for patients in need of a transplant. With demonstrated preclinical success, eGenesis is advancing programs in kidney transplantation, acute liver failure, and heart transplantation.
For more: https://egenesisbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.